About Aurum Biosciences
Aurum Biosciences is a Healthcare company based in Glasgow (United Kingdom) founded in 2015. Novel oxygen carriers and MRI software for stroke are developed. Aurum Biosciences has raised $6.3 million across 3 funding rounds from investors including Scottish Enterprise, Infinion BioPharma and InnoScot. The company has 6 employees. Aurum Biosciences offers products and services including ABL-101 and ABL-101 Platform. Its focus areas include Life Sciences, Neurology, Drugs and Stroke. Its legal entity is AURUM BIOSCIENCES LIMITED.
Company details
Aurum Biosciences was founded in 2015 in Glasgow, United Kingdom, as a biopharmaceutical company. Novel perfluorocarbon-based oxygen carriers, known as Oxycyte, are combined with proprietary software and MRI imaging to form the Glasgow Oxygen Level Dependent (GOLD) technology. This is advanced through preclinical development and clinical studies for acute ischaemic stroke, serving as both a diagnostic tool and therapeutic option, with potential follow-on indications.
- Headquarters Glasgow, United Kingdom
- Employees 6
- SectorsHealthcare
- Email••••••••
- Website aurumbiosciences.com
- Social LinkedIn X
- Legal Name Aurum Biosciences Limited
- Date of Incorporation 01 Nov, 2010
- Jurisdiction GLASGOW, SCOTLAND
- Total Equity Funding$6.3M (USD)
in 3 rounds
- Latest Funding Round$926.33K (USD), Series A
Jan 2024
- InvestorsScottish Enterprise
& 7 more
- Employee Count6
Products & Services of Aurum Biosciences
Aurum Biosciences offers a comprehensive portfolio of products and services, including ABL-101 and ABL-101 Platform.
Injectable for oxygen delivery in stroke and spinal injury treatment
Platform for therapeutics and diagnostics in inflammation and oncology
Funding Insights of Aurum Biosciences
Aurum Biosciences has successfully raised a total of $6.3M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $926.33 thousand completed in January 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.3M
- Total Rounds 3
- Last Round Series A — $926,326
- First Round $4.5M
(Sep 2015)
- Investors Count 8
All 3 funding rounds of Aurum Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $926,326 | Series A | – | InnoScot | |
| Oct 2020 | $873,932 | Seed | – | Infinion BioPharma, Scottish Investment Bank | – |
| Sep 2015 | $4.5M | Seed | – | – |
8 investors in total: 7 institutional and 1 angel.
Investors in Aurum Biosciences
Aurum Biosciences has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Scottish Enterprise, Infinion BioPharma and InnoScot.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage Scottish companies are supported with investment and expertise. | tricapital.co.uk | Melrose, United Kingdom | ||
Supports healthcare innovation by assessing ideas, protecting IP, and facilitating commercial deals. | 2002 | innoscot.com | Glasgow, United Kingdom | |
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom | |
Small molecule therapeutics are developed for infections and pain management. | 2018 | infinionbiopharma.com | Ahmedabad, India | |
| scottish-enterprise.com/sib | ||||
InnoScot Health is engaged in supporting NHS-led healthcare innovation. | shil.co.uk | Glasgow, United Kingdom | ||
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom | ||
CS Celestine Santosh | unknown_535348764b1e477a9 |
Investor details for Aurum Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aurum Biosciences
5 people are tracked at Aurum Biosciences (3 in leadership, 2 in board & advisors); the tracked headcount is 6.
| Name | Role | Group |
|---|---|---|
David Brennan | CEO | Leadership |
Graeme Deuchar | R&D Director | Leadership |
Govind Chavada | Executive Director | Leadership |
Graham Watson | Chairperson | Board & advisors |
Celestine Santosh | Scientific Advisor | Board & advisors |
Complete people profiles for Aurum Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Aurum Biosciences
3 dated milestones of Aurum Biosciences across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Aurum Biosciences is founded.
- Funding First funding round of $4.5M.
- Funding Latest funding round, Series A, of $926K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aurum Biosciences
Complete news archive for Aurum Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aurum Biosciences
Aurum Biosciences was founded in 2015.
Aurum Biosciences is headquartered in Glasgow, United Kingdom. It is registered at Glasgow, Scotland, United Kingdom.
Aurum Biosciences is a funded company, having raised a total of $6.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $4.5M, raised on Sep 2015.
Aurum Biosciences has 6 employees.
Aurum Biosciences was founded in 2015 in Glasgow, United Kingdom, as a biopharmaceutical company. Novel perfluorocarbon-based oxygen carriers, known as Oxycyte, are combined with proprietary software and MRI imaging to form the Glasgow Oxygen Level Dependent (GOLD) technology. This is advanced through preclinical development and clinical studies for acute ischaemic stroke, serving as both a diagnostic tool and therapeutic option, with potential follow-on indications.
Aurum Biosciences offers ABL-101 and ABL-101 Platform.
Aurum Biosciences has 8 investors. Key investors include Scottish Enterprise, Infinion BioPharma, InnoScot, TRICAPITAL Angels, and Celestine Santosh.
Aurum Biosciences operates through Aurum Biosciences Limited.